secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immix Biopharma, Inc. (IMMX)
CIK:        0001873835
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001493152-25-026500
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immix Biopharma reports 75% CR rate in Phase 2 NXC-201 for AL amyloidosis, BLA plan 2026
--------------------------------------------------------------------------------

- NXC-201 achieved 75% complete response (15/20) by independent review committee in relapsed/refractory AL amyloidosis.
- MRD negativity in 4 of 5 pending patients suggests future CR rate could reach 95%.
- Organ responses observed in 70% of evaluable patients; no neurotoxicity and only low-grade CRS (median 1 day).
- NEXICART-2 final readout and BLA submission planned for 2026; therapy has FDA RMAT and orphan designations.
- Current standard-of-care CR rate in this setting is under 10%, highlighting high unmet need.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873835/000149315225026500/0001493152-25-026500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873835/000149315225026500/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-026500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer